Trial intelligence / Profile preview

Phase II dasatinib in advanced cancers with DDR2 or inactivating BRAF mutations

2011-003128-11Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Jan 2012

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1